Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat.
adipose tissue
cancer
obesity
prostate
transcriptomic econvolution
transcriptomics
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
01 May 2019
01 May 2019
Historique:
received:
14
03
2019
accepted:
04
04
2019
pubmed:
9
4
2019
medline:
9
4
2019
entrez:
9
4
2019
Statut:
ppublish
Résumé
Prostate cancer is a leading cause of morbidity and cancer-related death worldwide. Androgen deprivation therapy (ADT) is the cornerstone of management for advanced disease. The use of these therapies is associated with multiple side effects, including metabolic syndrome and truncal obesity. At the same time, obesity has been associated with both prostate cancer development and disease progression, linked to its effects on chronic inflammation at a tissue level. The connection between ADT, obesity, inflammation and prostate cancer progression is well established in clinical settings; however, an understanding of the changes in adipose tissue at the molecular level induced by castration therapies is missing. Here, we investigated the transcriptional changes in periprostatic fat tissue induced by profound ADT in a group of patients with high-risk tumours compared to a matching untreated cohort. We find that the deprivation of androgen is associated with a pro-inflammatory and obesity-like adipose tissue microenvironment. This study suggests that the beneficial effect of therapies based on androgen deprivation may be partially counteracted by metabolic and inflammatory side effects in the adipose tissue surrounding the prostate.
Identifiants
pubmed: 30959474
doi: 10.1530/EC-19-0029
pii: EC-19-0029
pmc: PMC6499921
doi:
pii:
Types de publication
Journal Article
Langues
eng
Pagination
547-558Références
J Clin Endocrinol Metab. 2006 Apr;91(4):1305-8
pubmed: 16434464
Transplantation. 2017 Nov;101(11):2731-2738
pubmed: 28594751
J Natl Cancer Inst. 1997 Mar 5;89(5):385-9
pubmed: 9060961
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Int J Obes (Lond). 2015 May;39(5):869-73
pubmed: 25520251
Curr Opin Clin Nutr Metab Care. 2008 Nov;11(6):693-700
pubmed: 18827572
Lancet. 2002 Oct 12;360(9340):1155-62
pubmed: 12387968
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Bioinformatics. 2017 Feb 1;33(3):414-424
pubmed: 27694195
J Stat Softw. 2017;76:
pubmed: 36568334
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
BJU Int. 2011 Oct;108(8 Pt 2):E202-10
pubmed: 21443656
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Lancet Oncol. 2014 May;15(6):592-600
pubmed: 24739897
Eur Urol. 2015 Jun;67(6):1028-1038
pubmed: 25301760
Endocr Relat Cancer. 2018 May;25(5):561-568
pubmed: 29661963
Rev Urol. 2004 Spring;6(2):73-81
pubmed: 16985580
Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):240-6
pubmed: 20404727
Crit Rev Oncol Hematol. 2008 Nov;68(2):172-7
pubmed: 18706829
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
BJU Int. 2015 Apr;115 Suppl 5:3-13
pubmed: 25327530
Diabetes. 2012 Feb;61(2):346-54
pubmed: 22190646
Am J Epidemiol. 1984 Aug;120(2):244-50
pubmed: 6465122
PLoS One. 2017 Mar 16;12(3):e0173926
pubmed: 28301569
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2062-8
pubmed: 16123319
J Natl Cancer Inst. 2009 Jun 16;101(12):878-87
pubmed: 19509351
Urology. 2001 Nov;58(5):723-8
pubmed: 11711349
Ann N Y Acad Sci. 2000 May;904:437-48
pubmed: 10865787
Dermatoendocrinol. 2011 Apr;3(2):62-4
pubmed: 21695013
Endocr Relat Cancer. 2018 May;25(5):569-581
pubmed: 29592867
J Urol. 2009 Oct;182(4):1621-7
pubmed: 19683746
Biochem Biophys Res Commun. 2016 Sep 2;477(4):895-901
pubmed: 27392713
Crit Rev Food Sci Nutr. 2015;55(2):227-41
pubmed: 24915409
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Cell Physiol Biochem. 2012;29(1-2):233-40
pubmed: 22415092
Front Immunol. 2014 Feb 05;5:22
pubmed: 24600447
J Clin Oncol. 2004 Feb 1;22(3):439-45
pubmed: 14691120
Am J Pathol. 2014 Nov;184(11):2951-64
pubmed: 25219356
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):345-53
pubmed: 11319175
Mol Oncol. 2017 Sep;11(9):1241-1262
pubmed: 28618162
Pathology. 2012 Apr;44(3):204-8
pubmed: 22406482
Clin Cancer Res. 2017 May 1;23(9):2169-2176
pubmed: 28151719
BJU Int. 2011 Jun;107(12):1918-22
pubmed: 21044246
J Exp Med. 2017 Jun 5;214(6):1581-1592
pubmed: 28484078
J Exp Clin Cancer Res. 2012 Apr 02;31:32
pubmed: 22469146
J Biol Chem. 2007 Mar 16;282(11):8317-24
pubmed: 17244623
J Clin Oncol. 2004 Feb 1;22(3):446-53
pubmed: 14691122
J Clin Invest. 2006 Oct;116(10):2571-9
pubmed: 17016550
Eur Urol. 2007 Aug;52(2):331-43
pubmed: 17507151
J Clin Endocrinol Metab. 2001 Sep;86(9):4261-7
pubmed: 11549659
Asian J Androl. 2017 Sep-Oct;19(5):579-585
pubmed: 27569002
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
Prostate Cancer. 2014;2014:230812
pubmed: 24864213
Nat Biotechnol. 2014 Sep;32(9):896-902
pubmed: 25150836
Int J Mol Sci. 2016 Jul 09;17(7):
pubmed: 27409607
J Urol. 2013 Dec;190(6):2061-6
pubmed: 23820055
Prostate Cancer Prostatic Dis. 2001;4(2):101-105
pubmed: 12497046
J Immunol. 2018 Oct 1;201(7):1843-1854
pubmed: 30127088
Prostate. 2003 May 1;55(2):140-6
pubmed: 12661039
Clin Sci (Lond). 2003 Feb;104(2):195-201
pubmed: 12546642
BJU Int. 2012 Mar;109(5):660-4
pubmed: 21895937